If you're pregnant — or trying to conceive — and you've just found out you carry an MTHFR variant, this article is for you. You may have searched online and found forums full of fear: stories of miscarriages attributed to MTHFR, warnings about prenatal vitamins being dangerous, urgent advice to take specific supplements immediately. That information landscape is genuinely frightening, and it's genuinely mixed up.

Here is the honest version: the science on MTHFR and pregnancy is more nuanced than either "it doesn't matter at all" or "it causes miscarriage." There are areas where the evidence is stronger (neural tube defects, folate form during early pregnancy) and areas where it is weaker (miscarriage causation). Understanding the difference matters — because what you do with this information should be grounded in what the research actually shows, not in the most alarming interpretation of it.

This article walks through the key questions, the actual evidence, and what you can do. Please discuss any changes to your prenatal supplementation with your OB, midwife, or maternal-fetal medicine specialist before acting on anything here.

The Question Everyone Is Asking

Does having MTHFR increase my risk of miscarriage?

This is, by far, the most common fear that brings people to research MTHFR in pregnancy. The short answer is: the research shows an association in some studies, but association is not causation, the effect size is often modest, the data are inconsistent across populations, and major medical organizations do not consider MTHFR a proven independent risk factor for miscarriage. [2]

The longer answer — which is the one that will actually help you — requires looking at what the studies say, where they disagree, and what's driving the confusion.

What Mainstream Medicine Says

The American College of Medical Genetics and Genomics (ACMG) issued a practice guideline explicitly stating that MTHFR polymorphism genotyping should not be ordered as part of the evaluation for recurrent pregnancy loss or thrombophilia. [2] This guidance was updated in 2020 and the position remains the same. [3] The rationale is straightforward: the clinical evidence for MTHFR variants as independent, causative risk factors is not strong enough to justify routine testing, and testing often leads to unnecessary intervention without clinical benefit.

The American College of Obstetricians and Gynecologists (ACOG), in its Practice Bulletin on inherited thrombophilias in pregnancy, likewise does not recommend MTHFR testing as part of standard thrombophilia workup in pregnancy. The guidelines reflect the same core concern: MTHFR variant status alone does not reliably predict adverse pregnancy outcomes in the way that other thrombophilias (like Factor V Leiden or antiphospholipid syndrome) do.

This is important context. It does not mean MTHFR is biologically irrelevant — it means the variant by itself, in isolation, is not a reliable enough predictor to drive clinical decisions. What drives clinical decisions is the downstream biomarker the variant influences: homocysteine.

What the Research Actually Shows About Miscarriage

Multiple meta-analyses have examined the association between MTHFR C677T and recurrent pregnancy loss. The results are genuinely mixed.

A 2006 meta-analysis of 21 studies found a modest but statistically significant association between C677T and unexplained recurrent pregnancy loss. [6] A larger 2013 pooled analysis supported a similar association, particularly for homozygous TT carriers, especially in Asian populations. [4] These studies suggest that homozygous C677T may carry some increased risk, at least in certain populations.

But there are critical caveats. Many of the positive associations disappear or weaken considerably when studies are limited to European populations, when publication bias is accounted for, or when confounding factors like nutritional status and folate intake are controlled. Heterozygous carriers — people with just one copy — rarely show a statistically significant increase in risk. And the mechanism proposed (MTHFR impairs folate metabolism, which raises homocysteine, which damages the developing pregnancy) is plausible, but it means the variant itself is not the direct cause. It is a predisposing factor that requires other conditions — specifically elevated homocysteine driven by inadequate folate and B12 — to become clinically meaningful.

Association is not causation. The MTHFR genotype predicts your enzyme efficiency. It does not determine your pregnancy outcome. [7]

Where the Evidence Is Stronger: Neural Tube Defects

The connection between MTHFR C677T and neural tube defects (NTDs) — spina bifida, anencephaly — is more consistent and more widely accepted than the miscarriage association. [8]

A large meta-analysis of 25 case-control studies found that maternal C677T homozygosity was associated with a meaningfully elevated risk of having a child with a neural tube defect. [9] The biological rationale is solid: the neural tube closes in the first 28 days after conception, often before a woman even knows she is pregnant. This process is critically dependent on adequate methylfolate for cell division and DNA methylation. A C677T homozygous woman whose MTHFR enzyme runs at roughly 30% efficiency has a demonstrably compromised ability to produce methylfolate during exactly this window. [15]

This is the strongest clinical argument for MTHFR-aware prenatal care: not because the genotype alone determines outcome, but because it defines a population where folate status — and specifically the form of folate — matters more than average.

Folic Acid vs. Methylfolate: Why the Form Matters

Nearly all standard prenatal vitamins use folic acid — the synthetic, oxidized form of folate. Folic acid requires conversion through several enzymatic steps before the body can use it, and one of those steps depends directly on the MTHFR enzyme. [10]

For a C677T homozygous woman whose MTHFR enzyme is running at 30–40% capacity, this conversion is significantly impaired. Folic acid accumulates in circulation as unmetabolized folic acid (UMFA), which competes with the real methylfolate at receptor sites without providing its function. The supplement that most prenatal vitamins are built around may be the form that least serves MTHFR carriers. [11]

The alternative is 5-methyltetrahydrofolate (5-MTHF), also called methylfolate, L-methylfolate, or Metafolin on supplement labels. This is the biologically active form — the form your body actually uses — and it does not require MTHFR conversion. A randomized trial found that supplementation with 5-MTHF was as effective as folic acid at maintaining maternal folate status overall, while substantially reducing unmetabolized folic acid accumulation. [12] For MTHFR carriers, the argument for starting with the active form is direct: it bypasses the enzyme that isn't working properly.

Prenatal vitamins containing methylfolate exist and are increasingly available. Brands like Seeking Health, Thorne, Pure Encapsulations, and several others now make prenatal formulas with 5-MTHF rather than folic acid. Look for "5-methyltetrahydrofolate," "methylfolate," "Metafolin," or "Quatrefolic" on the label.

Before switching your prenatal vitamin, talk to your OB or midwife. This is especially important if you are already pregnant. They may have specific guidance about timing and dosage, and they need to know what you are taking.

The Homocysteine Angle: The Biomarker That Actually Matters

Here is something the online MTHFR conversation often misses: the miscarriage and pregnancy complication risk that has been studied is driven not by the MTHFR genotype directly, but by what that genotype can cause — elevated homocysteine. [13]

Homocysteine is a metabolic byproduct that, in a well-functioning methylation cycle, gets converted back into methionine using methylfolate and B12. When the methylation cycle is impaired — by MTHFR variant, by poor folate status, by B12 deficiency, or by a combination — homocysteine accumulates.

A landmark prospective cohort study, the Hordaland Homocysteine Study, followed over 5,000 pregnant women and found that elevated total plasma homocysteine in early pregnancy was independently associated with increased risk of preeclampsia, placental abruption, preterm delivery, very low birth weight, and stillbirth. [14] This relationship between elevated homocysteine and adverse pregnancy outcomes is more consistent across studies than the MTHFR genotype association — because homocysteine is the functional output of the pathway, not just one of the genetic inputs.

What this means practically: knowing your MTHFR genotype is useful context, but measuring your homocysteine gives you the clinically actionable number. A C677T homozygous woman with normal homocysteine (below 10 micromol/L, optimally below 7) who is taking adequate methylfolate and B12 may face no meaningful increase in pregnancy risk from her variant. A woman with the same genotype and a homocysteine of 18 has a documented functional problem that needs to be addressed. The genotype is not the alarm. The biomarker is.

Ask your OB or midwife about having a total homocysteine level drawn — ideally before conception, or early in the first trimester. If it is elevated, that is the target to treat, with methylfolate, B12, and B6 guidance from your provider.

Practical Steps: What to Actually Do

The following is a framework for thinking through MTHFR in pregnancy — not a prescription. Every step here should be reviewed with your healthcare provider before you act on it.

  • Get your homocysteine tested. This is the single most important follow-up to knowing you carry an MTHFR variant. Ask for a "plasma total homocysteine" test. Optimal preconception range is below 7–8 micromol/L; many labs flag anything above 10 or 12 as elevated.
  • Switch to a methylfolate-based prenatal. If you are trying to conceive or are in early pregnancy and carry MTHFR C677T (especially homozygous), talk to your provider about switching to a prenatal that uses 5-MTHF rather than folic acid. The ideal time is before conception — the neural tube closes in the first four weeks, before most women have their first prenatal appointment.
  • Ensure your B12 is in the methyl form. Look for methylcobalamin on your prenatal or B12 supplement label, not cyanocobalamin. Folate and B12 work as a team; B12 adequacy is required for folate to move through the methylation cycle. Sublingual methylcobalamin has good absorption.
  • Check your B12 status directly. A serum B12 level, or a methylmalonic acid (MMA) test for a more functional measure, can tell you whether you're genuinely replete. B12 deficiency can cause elevated homocysteine independently of folate status.
  • Don't self-prescribe high-dose methylfolate. High doses of methylfolate (above 1,000–2,000 mcg, especially without guidance) can cause side effects in some people — anxiety, irritability, difficulty sleeping — particularly if B12 is not adequate. Start at standard prenatal doses (800–1,000 mcg of methylfolate is typical for a pregnancy-dosed formula) and adjust with your provider's input.

Additional Considerations for Compound Heterozygous Carriers

Compound heterozygous MTHFR — carrying one copy each of C677T and A1298C — is a distinct situation that deserves its own attention. Some research suggests that compound heterozygosity may reduce overall MTHFR enzyme function more than either variant alone, though the magnitude varies across studies. [5]

If you are compound heterozygous and pregnant or planning pregnancy, the same principles apply — prioritize methylfolate over folic acid, ensure adequate methylcobalamin, and measure homocysteine — but the case for doing so is, if anything, stronger than for single-variant carriers. The A1298C variant also affects BH4 production, which has downstream effects on neurotransmitter synthesis. This additional consideration may be worth discussing with a maternal-fetal medicine specialist who has experience with MTHFR.

See our dedicated article on compound heterozygous MTHFR for a more complete breakdown of what having both variants means for supplementation.

What Not to Do

The online MTHFR community, as well-intentioned as it often is, can drive people toward responses that range from unnecessary to genuinely counterproductive. Here are the specific things to avoid:

  • Don't panic about the genotype alone. An MTHFR variant — even homozygous C677T — does not determine your pregnancy outcome. Millions of women with MTHFR variants have uncomplicated pregnancies every year. The variant is one input into a metabolic system that has significant flexibility and can be supported.
  • Don't act on genotype without measuring the biomarker. If your homocysteine is normal and you are taking a good methylated prenatal, you may have nothing further to address. Don't escalate supplementation based on genotype alone.
  • Don't completely avoid folic acid in food. Naturally occurring folate in leafy greens, legumes, and citrus is not the same problem as synthetic folic acid in supplements and fortified foods. Whole-food folate sources do not carry the same unmetabolized accumulation concern and are part of a healthy pregnancy diet regardless of MTHFR status.
  • Don't substitute online advice for obstetric care. MTHFR status is one consideration in a pregnancy. Your OB or midwife needs to know your complete picture to advise you well. Bring what you've learned to that conversation — don't use it to replace the conversation.

Being Informed Without Being Overwhelmed

Finding out you have an MTHFR variant during pregnancy — or while trying to conceive — puts you in a difficult position. You're dealing with an internet that offers both "it's completely harmless, don't worry" and "it causes miscarriage and you need to overhaul everything immediately," sometimes in the same search results. Neither extreme is accurate.

The measured truth is that MTHFR variants affect how efficiently your body converts folate, and that efficiency matters most during early pregnancy for neural tube development. The miscarriage association is real in some studies but not firmly established as causal, particularly for heterozygous carriers. The biomarker that matters most — homocysteine — is measurable and treatable. The supplement change that makes the most sense — switching from folic acid to methylfolate in your prenatal — is practical, accessible, and well-supported by the logic of the underlying biology even where the clinical trial data are still catching up. [11][12]

You can act on what is known without catastrophizing about what is uncertain. That combination — informed action plus perspective — is the goal.

If you want to understand the full methylation picture beyond MTHFR alone — including how your other genes interact with these variants and how to build a supplement protocol that reflects your actual genetic combination — that is what Whole Gene Health was designed for.